Publications by authors named "T B Plaksina"

Unlabelled: . Previously, 24-week results of phase III double-blind, placebo-controlled randomized clinical study (SOLAR) of levilimab in subjects with active rheumatoid arthritis (RA) proved a superiority of levilimab over placebo. Here, we present 1-year efficacy and safety data of the SOLAR study.

View Article and Find Full Text PDF

Objective: To evaluate the effectiveness of the Cytoflavin in patients with dyscirculatory encephalopathy (DE) who had a new coronavirus infection.

Material And Methods: 82 patients were examined: 16 (19.5%) men and 66 (80.

View Article and Find Full Text PDF

Objectives: Netakimab (NTK) is a humanised monoclonal antibody targeting interleukin-17A, previously investigated in a phase 1 trial in healthy volunteers. Here, we report the results of a phase 2 trial, conducted to assess safety and pharmacokinetics (PK), to establish a therapeutic dose of NTK in a target population of patients with active ankylosing spondylitis (AS).

Methods: 89 patients with active AS, despite non-steroidal anti-inflammatory (NSAID) drug treatment, were randomised to receive 40, 80 or 120 mg of subcutaneous NTK or placebo at weeks 0, 1, 2 and q2wk thereafter until week 12.

View Article and Find Full Text PDF

What is the emotional valence of family life and what factors contribute to this valence? Research indicates that most people are mildly happy but also that the years devoted to raising children are associated with diminished happiness and well-being, particularly for mothers. Public discourse is increasingly concerned that parenthood does not make us happy, but little empirical work has actually studied the emotional valence of family life. We addressed this gap in the literature with an intensive examination of the emotional valence of dual-earner family life.

View Article and Find Full Text PDF

A study was made of the content of alpha-fetoprotein (alpha-FP) in the blood serum and of proliferative processes in hepatoma 22A-bearing mice after injection of cyclophosphamide in a dose of 150 mg/kg at varying time of 4-day tumor growth. The data obtained indicate that the time of appearance of alpha-FP in the blood, the pattern of rhythmic fluctuations in protein content and in the number of DNA-synthesizing and mitotic cells of the tumor depend on the time of the cytostatic injection during the day. Besides, cyclophosphamide exerts a more powerful inhibitory effect on the content of alpha-FP in the blood serum and less powerful on the proliferative processes in hepatoma 22A.

View Article and Find Full Text PDF